Acquisitions and Divestitures - Purchase Price Allocation for Year Ended 2016 (Details) $ in Millions					6 Months Ended		12 Months Ended
		Mar. 01, 2016 USD ($)	Jan. 22, 2016 USD ($)	May 01, 2015 product	Dec. 31, 2015 USD ($) product		Dec. 31, 2017 USD ($) product	Dec. 31, 2016 USD ($) product		Jun. 27, 2015 USD ($) product
Assets acquired:
Goodwill					$ 5,152.7		$ 4,175.4	$ 4,049.4		$ 4,721.2
Liabilities assumed:
Business combination, number of products purchased | product							3	2		2
Tretinoin Products
Business Acquisition [Line Items]
Purchase price paid			$ 416.4
Contingent consideration			0.0
Total purchase consideration			416.4
Assets acquired:
Cash and cash equivalents			0.0
Accounts receivable			0.0
Inventories			1.4
Prepaid expenses and other current assets			0.0
Property, plant and equipment, net			0.0
Goodwill			1.7
Indefinite-lived intangibles:
Total intangible assets			413.3
Total assets			416.4
Liabilities assumed:
Accounts payable			0.0
Accrued liabilities			0.0
Long-term debt			0.0
Net deferred income tax liabilities			0.0
Total liabilities			0.0
Net assets acquired			416.4
Tretinoin Products | In-process research and development
Indefinite-lived intangibles:
Indefinite-lived intangibles			0.0
Tretinoin Products | Distribution and license agreements, supply agreements
Definite-lived intangibles:
Definite-lived intangibles			0.0
Tretinoin Products | Developed product technology, formulations, and product rights
Definite-lived intangibles:
Definite-lived intangibles			411.0
Tretinoin Products | Customer relationships and distribution networks
Definite-lived intangibles:
Definite-lived intangibles			0.0
Tretinoin Products | Non-compete agreements
Definite-lived intangibles:
Definite-lived intangibles			$ 2.3
Development-Stage Rx Products
Business Acquisition [Line Items]
Purchase price paid		$ 0.0
Contingent consideration		24.9
Total purchase consideration		24.9
Assets acquired:
Cash and cash equivalents		0.0
Accounts receivable		0.0
Inventories		0.0
Prepaid expenses and other current assets		0.0
Property, plant and equipment, net		0.0
Goodwill		0.0
Indefinite-lived intangibles:
Total intangible assets		24.9
Total assets		24.9
Liabilities assumed:
Accounts payable		0.0
Accrued liabilities		0.0
Long-term debt		0.0
Net deferred income tax liabilities		0.0
Total liabilities		0.0
Net assets acquired		24.9
Business combination, number of products purchased | product				2
Development-Stage Rx Products | In-process research and development
Indefinite-lived intangibles:
Indefinite-lived intangibles		24.9
Development-Stage Rx Products | Distribution and license agreements, supply agreements
Definite-lived intangibles:
Definite-lived intangibles		0.0
Development-Stage Rx Products | Developed product technology, formulations, and product rights
Definite-lived intangibles:
Definite-lived intangibles		0.0
Development-Stage Rx Products | Customer relationships and distribution networks
Definite-lived intangibles:
Definite-lived intangibles		0.0
Development-Stage Rx Products | Non-compete agreements
Definite-lived intangibles:
Definite-lived intangibles		$ 0.0
All Other
Business Acquisition [Line Items]
Purchase price paid					15.3	[1]		$ 17.1	[2]
Contingent consideration					13.9	[1]		26.2	[2]
Total purchase consideration					29.2	[1]		43.3	[2]
Assets acquired:
Cash and cash equivalents					0.0	[1]		3.8	[2]
Accounts receivable					0.0	[1]		4.9	[2]
Inventories					0.0	[1]		7.1	[2]
Prepaid expenses and other current assets	[2]							0.1
Property, plant and equipment, net	[2]							1.2
Goodwill					0.0	[1]		0.0	[2]
Indefinite-lived intangibles:
Total intangible assets					29.2	[1]		32.9	[2]
Total assets					29.2	[1]		50.0	[2]
Liabilities assumed:
Accounts payable					0.0	[1]		2.8	[2]
Accrued liabilities					0.0	[1]		0.1	[2]
Long-term debt	[2]							3.3
Net deferred income tax liabilities					0.0	[1]		0.5	[2]
Total liabilities					0.0	[1]		6.7	[2]
Net assets acquired					$ 29.2	[1]		$ 43.3	[2]
Business combination, number of products purchased | product					8			4
All Other | In-process research and development
Indefinite-lived intangibles:
Indefinite-lived intangibles					$ 29.2	[1]		$ 4.9	[2]
All Other | Distribution and license agreements, supply agreements
Definite-lived intangibles:
Definite-lived intangibles					0.0	[1]		1.8	[2]
All Other | Developed product technology, formulations, and product rights
Definite-lived intangibles:
Definite-lived intangibles					0.0	[1]		18.0	[2]
All Other | Customer relationships and distribution networks
Definite-lived intangibles:
Definite-lived intangibles					0.0	[1]		8.2	[2]
All Other | Non-compete agreements
Definite-lived intangibles:
Definite-lived intangibles					$ 0.0	[1]		$ 0.0	[2]

[1] Consists of eight product development acquisitions in our CHCA, CHCI and RX segments.

[2] Consists of four product acquisitions in our CHCA, CHCI and RX segments.